Candriam SCA’s AbbVie ABBV Stock Holding History

Candriam SCA’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$249M	Buy	1,144,668 +67,035	+6%	+$14.9M	1.29%	8
2025 Q4	$246M	Buy	1,077,633 +241,917	+29%	+$55.1M	1.23%	9
2025 Q3	$194M	Buy	835,716 +259,924	+45%	+$52.9M	1.01%	14
2025 Q2	$107M	Buy	575,792 +174,294	+43%	+$32.4M	0.62%	29
2025 Q1	$84.1M	Sell	401,498 -13,340	-3%	-$2.59M	0.53%	36
2024 Q4	$73.7M	Buy	414,838 +27,616	+7%	+$5.08M	0.42%	49
2024 Q3	$76.5M	Buy	387,222 +154,741	+67%	+$28.9M	0.44%	48
2024 Q2	$39.9M	Sell	232,481 -12,005	-5%	-$1.99M	0.24%	91
2024 Q1	$44.5M	Buy	244,486 +23,834	+11%	+$4.11M	0.28%	77
2023 Q4	$34.2M	Buy	220,652 +8,839	+4%	+$1.29M	0.24%	96
2023 Q3	$31.6M	Sell	211,813 -3,372	-2%	-$495K	0.22%	94
2023 Q2	$29M	Buy	215,185 +15,561	+8%	+$2.28M	0.21%	123
2023 Q1	$29.3M	Sell	199,624 -50,552	-20%	-$7.73M	0.2%	122
2022 Q4	$40.4M	Sell	250,176 -69,902	-22%	-$10.7M	0.27%	87
2022 Q3	$43M	Sell	320,078 -11,723	-4%	-$1.68M	0.3%	76
2022 Q2	$50.8M	Sell	331,801 -28,037	-8%	-$4.28M	0.42%	59
2022 Q1	$58.3M	Buy	359,838 +16,981	+5%	+$2.47M	0.4%	60
2021 Q4	$46.4M	Sell	342,857 -7,930	-2%	-$937K	0.3%	81
2021 Q3	$37.8M	Sell	350,787 -1,069	-0.3%	-$122K	0.26%	94
2021 Q2	$39.6M	Sell	351,856 -178,225	-34%	-$20.1M	0.27%	85
2021 Q1	$54.6M	Buy	530,081 +14	+0%	+$1.5K	0.45%	49
2020 Q4	$56.8M	Sell	530,067 -135,741	-20%	-$13M	0.45%	49
2020 Q3	$58.3M	Buy	665,808 +2,238	+0.3%	+$211K	0.55%	35
2020 Q2	$65.2M	Sell	663,570 -78,451	-11%	-$6.91M	0.69%	24
2020 Q1	$64.2M	Hold	742,021	–	–	0.71%	21
2019 Q4	$65.7M	Sell	742,021 -122,092	-14%	-$10.1M	0.7%	21
2019 Q3	$65.4M	Buy	864,113 +318,994	+59%	+$21.9M	0.87%	18
2019 Q2	$39.5M	Sell	545,119 -21,394	-4%	-$1.68M	0.49%	36
2019 Q1	$45.7M	Buy	566,513 +19,159	+4%	+$1.57M	0.58%	30
2018 Q4	$50.5M	Buy	547,354 +26,953	+5%	+$2.37M	0.78%	22
2018 Q3	$49.2M	Buy	520,401 +8,017	+2%	+$760K	0.65%	26
2018 Q2	$47.5M	Buy	512,384 +180,525	+54%	+$17.6M	0.75%	20
2018 Q1	$31.4M	Buy	331,859 +50,033	+18%	+$5.5M	0.54%	33
2017 Q4	$27.3M	Buy	281,826 +64,410	+30%	+$6.07M	0.47%	47
2017 Q3	$19.3M	Sell	217,416 -9,100	-4%	-$693K	0.34%	78
2017 Q2	$16.4M	Sell	226,516 -224,418	-50%	-$15.1M	0.31%	81
2017 Q1	$29.4M	Buy	450,934 +221,678	+97%	+$13.9M	0.57%	29
2016 Q4	$14.4M	Sell	229,256 -226,556	-50%	-$13.8M	0.33%	78
2016 Q3	$28.7M	Buy	455,812 +377,252	+480%	+$24.4M	0.69%	29
2016 Q2	$4.86M	Sell	78,560 -609,110	-89%	-$37.1M	0.13%	186
2016 Q1	$39.1M	Buy	687,670 +129,988	+23%	+$7.25M	0.98%	17
2015 Q4	$33M	Sell	557,682 -5,881	-1%	-$339K	0.88%	22
2015 Q3	$30.7M	Buy	563,563 +27,428	+5%	+$1.79M	0.75%	21
2015 Q2	$36M	Buy	536,135 +70,584	+15%	+$4.61M	0.75%	22
2015 Q1	$27.3M	Sell	465,551 -97,420	-17%	-$5.89M	0.55%	41
2014 Q4	$36.8M	Buy	+562,971	New	+$35.5M	0.77%	20

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Candriam SCA's ABBV Position: Q1 2026 in Review

Candriam SCA increased its AbbVie (ABBV) stake by 6.2% in Q1 2026, buying an estimated $14.9M and bringing the position to 1,144,668 shares worth $249M. The position accounts for 1.29% of the portfolio, ranked #8.

Candriam SCA first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Candriam SCA held 1,144,668 shares of AbbVie worth $249M as of Q1 2026.
Candriam SCA bought 67,035 AbbVie shares in Q1 2026, an estimated $14.9M.
AbbVie made up 1.29% of Candriam SCA's portfolio in Q1 2026, its #8 holding.
Candriam SCA first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.